405 related articles for article (PubMed ID: 30386930)
1. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Finberg JPM
J Neural Transm (Vienna); 2019 Apr; 126(4):433-448. PubMed ID: 30386930
[TBL] [Abstract][Full Text] [Related]
2. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
5. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
Youdim MB; Riederer P
J Neural Transm Gen Sect; 1993; 91(2-3):181-95. PubMed ID: 8390270
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
8. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
9. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
10. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.
Napolitano A; Cesura AM; Da Prada M
J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607
[TBL] [Abstract][Full Text] [Related]
11. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
12. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
[TBL] [Abstract][Full Text] [Related]
13. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
15. The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat.
Odlind C; Reenilä I; Männistö PT; Ekblom J; Hansell P
Pflugers Arch; 2001 Jul; 442(4):505-10. PubMed ID: 11510881
[TBL] [Abstract][Full Text] [Related]
16. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chan P;
Parkinsonism Relat Disord; 2014 Oct; 20(10):1041-5. PubMed ID: 25034874
[TBL] [Abstract][Full Text] [Related]
17. Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function.
Wang Y; Berndt TJ; Gross JM; Peterson MA; So MJ; Knox FG
Am J Physiol Regul Integr Comp Physiol; 2001 Jan; 280(1):R248-54. PubMed ID: 11124158
[TBL] [Abstract][Full Text] [Related]
18. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney.
Sampaio-Maia B; Moreira-Rodrigues M; Pestana M
Nephron Physiol; 2006; 103(1):p14-24. PubMed ID: 16352914
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
Mazumder MK; Borah A; Choudhury S
Med Hypotheses; 2020 Apr; 137():109544. PubMed ID: 31954292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
